PBYI · XBRL financial data

Puma Biotechnology financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (PBYI's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	225	253	228	236	230	228
Cost of goods and services sold	39	64	55	63	64	58
Research and development	98	72	—	—	—	—
Selling, general and administrative	118	116	90	90	80	71
Total operating expenses	256	—	—	—	—	—
Operating income (loss)	(30)	1	24	33	31	37
Interest income	0	0	1	3	5	4
Interest expense	14	13	12	13	12	7
Other income (expense)	0	0	(0)	1	1	1
Income tax expense (benefit)	0	0	0	1	(6)	5
Net income (loss)	(60)	(29)	0	22	30	31
Earnings per share, basic USD per share	(1.52)	(29,126.00)	0.00	0.46	0.62	0.62
Earnings per share, diluted USD per share	(1.52)	(0.72)	0.00	0.45	0.62	0.61
Weighted average shares, basic millions of shares	40	41	45	47	49	50
Weighted average shares, diluted millions of shares	40	41	45	48	49	51

Fiscal years (PBYI's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	85	63	76	85	69	30
Marketable securities	8	19	5	11	32	68
Accounts receivable	26	33	40	48	32	54
Inventory	3	7	5	7	9	6
Prepaid and other current assets	11	—	—	—	—	—
Total current assets	146	140	134	156	148	163
Property and equipment, net	2	2	1	1	1	0
Right-of-use asset	16	14	11	8	5	5
Total assets	244	227	222	231	213	216
Accounts payable	12	11	6	7	6	5
Accrued liabilities	61	93	53	53	37	50
Current portion of long-term debt	14	0	0	34	45	23
Total current liabilities	114	110	77	99	96	81
Long-term debt	84	97	98	66	22	0
Lease liability, non-current	20	16	12	7	1	5
Total liabilities	250	229	200	177	121	86
Accumulated deficit	(1,338)	(1,367)	(1,367)	(1,345)	(1,315)	(1,284)
Total stockholders' equity	(6)	(2)	22	53	92	130
Total liabilities and equity	244	227	222	231	213	216
Common shares outstanding (cover page) millions of shares	40	41	47	48	50	51

Fiscal years (PBYI's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(60)	(29)	0	22	30	31
Stock-based compensation	37	33	12	10	8	7
Net cash from operating activities	1	21	(16)	27	39	42
Purchases of property and equipment	0	0	0	0	0	0
Net cash from investing activities	23	(11)	7	(19)	(20)	(36)
Net cash from financing activities	0	(32)	12	0	(34)	(45)
Net change in cash	24	(22)	4	8	(15)	(40)

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Puma Biotechnology	37	57	1.6*	51.6M	—	Q2 FY26 10-QJun 30, 2026
Eledon Pharmaceuticals	6.8	not reported	(23)*	81.3M	3.9 quarters	Q2 FY26 10-QJun 30, 2026
Neurogene	112	not reported	(24)*	20.0M	9.5 quarters	Q2 FY26 10-QJun 30, 2026
Voyager Therapeutics	36	3.2	(26)*	61.6M	4.5 quarters	Q2 FY26 10-QJun 30, 2026
Aclaris Therapeutics	19	1.6	(20)*	147.2M	4.6 quarters	Q2 FY26 10-QJun 30, 2026
Alpha Cognition	41	6.1	(6.9)*	21.8M	6.0 quarters	Q2 FY26 10-QJun 30, 2026
Sangamo Therapeutics	28	1.4	(19)	414.3M	1.4 quarters	Q1 FY26 10-QMar 31, 2026
Vistagen Therapeutics	17	not reported	(15)	44.4M	2.2 quarters	Q1 FY27 10-QJun 30, 2026
Monopar Therapeutics	53	0*	(3.2)*	6.7M	32.4 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.